(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride

(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
Trade Name
Orphan Indication C1-inhibitor-dependent angioedema (including prevention and treatment of attacks)
USA Market Approval USA
USA Designation Date 2017-11-01 00:00:00
Sponsor BioCryst Pharmaceuticals, Inc.;4505 Emperor Blvd, Suite 200200;Durham, North Carolina, 27703